JP2023519158A5 - - Google Patents
Info
- Publication number
- JP2023519158A5 JP2023519158A5 JP2022553649A JP2022553649A JP2023519158A5 JP 2023519158 A5 JP2023519158 A5 JP 2023519158A5 JP 2022553649 A JP2022553649 A JP 2022553649A JP 2022553649 A JP2022553649 A JP 2022553649A JP 2023519158 A5 JP2023519158 A5 JP 2023519158A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical composition
- composition according
- medically acceptable
- remdesivir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025129731A JP2025166040A (ja) | 2020-03-23 | 2025-08-01 | 抗ウイルス化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993121P | 2020-03-23 | 2020-03-23 | |
| US62/993,121 | 2020-03-23 | ||
| PCT/US2021/070300 WO2021195661A1 (en) | 2020-03-23 | 2021-03-23 | Anti-viral compounds and methods for administration thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025129731A Division JP2025166040A (ja) | 2020-03-23 | 2025-08-01 | 抗ウイルス化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519158A JP2023519158A (ja) | 2023-05-10 |
| JP2023519158A5 true JP2023519158A5 (https=) | 2024-04-19 |
Family
ID=77890599
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553649A Pending JP2023519158A (ja) | 2020-03-23 | 2021-03-23 | 抗ウィルス化合物 |
| JP2025129731A Pending JP2025166040A (ja) | 2020-03-23 | 2025-08-01 | 抗ウイルス化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025129731A Pending JP2025166040A (ja) | 2020-03-23 | 2025-08-01 | 抗ウイルス化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20230263778A1 (https=) |
| EP (2) | EP4110330A4 (https=) |
| JP (2) | JP2023519158A (https=) |
| KR (2) | KR20250126146A (https=) |
| CN (2) | CN115697328A (https=) |
| AU (2) | AU2021244718A1 (https=) |
| BR (1) | BR112022018236A2 (https=) |
| CA (2) | CA3170367A1 (https=) |
| CL (1) | CL2022002481A1 (https=) |
| CO (1) | CO2022014073A2 (https=) |
| CR (1) | CR20220491A (https=) |
| DO (1) | DOP2022000185A (https=) |
| EC (1) | ECSP22076862A (https=) |
| IL (2) | IL296152A (https=) |
| MX (2) | MX2022011370A (https=) |
| PE (1) | PE20221868A1 (https=) |
| PH (1) | PH12022552324A1 (https=) |
| WO (1) | WO2021195661A1 (https=) |
| ZA (1) | ZA202211060B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021195661A1 (en) * | 2020-03-23 | 2021-09-30 | Gregg John M H | Anti-viral compounds and methods for administration thereof |
| CA3172483A1 (en) | 2020-04-06 | 2021-10-14 | Scott Ellis | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| PE20230618A1 (es) | 2020-06-24 | 2023-04-14 | Gilead Sciences Inc | Analogos de nucleosido de 1'-ciano y usos de los mismos |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| WO2023075714A1 (en) * | 2021-10-25 | 2023-05-04 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder compositions comprising anti-viral agents |
| IT202100029909A1 (it) * | 2021-11-26 | 2023-05-26 | Craniomed Group S R L | Combinazione di uno o più antibiotici della classe delle ansamicine con uno o più altri antibiotici per la prevenzione e il trattamento di infezioni causate da coronavirus, delle relative malattie e degli effetti clinici indotti dalle tossine prodotte a seguito dell’infezione da coronavirus. |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| CN114568490B (zh) * | 2022-04-01 | 2023-12-19 | 眉山职业技术学院(眉山技师学院) | 雷帕霉素在抑制柑橘青霉菌生长中的应用 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| KR20260016489A (ko) * | 2023-05-30 | 2026-02-03 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제를 제조하는 피릴륨 방법 |
| CN120983460A (zh) * | 2025-09-25 | 2025-11-21 | 中国农业科学院饲料研究所 | 泰乐菌素衍生物在制备抗痘病毒科病毒药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2326763A1 (en) * | 1998-04-30 | 1999-11-11 | Theodore O. Johnson, Jr. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and methods for their synthesis |
| US20040115268A1 (en) * | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| US20050164994A1 (en) * | 2001-12-10 | 2005-07-28 | Control Deliver Systems, Inc. | Treatment of genitourinary tract disorders |
| TW200500067A (en) * | 2003-01-21 | 2005-01-01 | Control Delivery Sys Inc | Salts of codrugs and uses related thereto |
| WO2005113580A1 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| CN101039701A (zh) * | 2004-08-26 | 2007-09-19 | 尼古拉斯皮拉马尔印度有限公司 | 含有生物可裂解二硫化物连接物的前药和共药 |
| EP1868653A2 (en) * | 2005-04-12 | 2007-12-26 | PSivida Inc. | Hmgcoa reductase inhibitor codrugs and uses thereof |
| WO2007016306A2 (en) * | 2005-08-01 | 2007-02-08 | Psivida Inc. | HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF |
| WO2008094507A2 (en) * | 2007-01-26 | 2008-08-07 | Cellicon Biotechnologies, Inc. | Novel fusion compounds |
| US20170044096A1 (en) * | 2013-03-15 | 2017-02-16 | Rutgers, The State University Of New Jersey | Augmenting Moieties for Anti-Inflammatory Compounds |
| WO2012138911A2 (en) * | 2011-04-05 | 2012-10-11 | The Administrators Of The Tulane Educational Fund | Conjugates of anti-hiv drugs and somatostatin analogs |
| WO2015051268A2 (en) * | 2013-10-04 | 2015-04-09 | The Johns Hopkins University | Hiv protease inhibitors against picornavirus infection |
| DK3785717T3 (da) * | 2015-09-16 | 2022-03-21 | Gilead Sciences Inc | Fremgangsmåder til behandling af coronaviridae-infektioner |
| EP3863453A4 (en) * | 2018-10-18 | 2022-11-23 | Qnovia, Inc. | ELECTRONIC DEVICE FOR GENERATION OF AN AEROSOL FOR INHALATION BY A PERSON |
| US20230157998A1 (en) * | 2020-03-06 | 2023-05-25 | Pfizer Inc. | Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019 |
| WO2021194927A1 (en) * | 2020-03-22 | 2021-09-30 | Tlc Biopharmaceuticals, Inc. | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases |
| WO2021195661A1 (en) * | 2020-03-23 | 2021-09-30 | Gregg John M H | Anti-viral compounds and methods for administration thereof |
| CN111450088B (zh) * | 2020-04-30 | 2021-08-03 | 上海爱启医药技术有限公司 | 二杨梅素基二硒醚的药物应用 |
-
2021
- 2021-03-23 WO PCT/US2021/070300 patent/WO2021195661A1/en not_active Ceased
- 2021-03-23 CR CR20220491A patent/CR20220491A/es unknown
- 2021-03-23 EP EP21775547.9A patent/EP4110330A4/en active Pending
- 2021-03-23 CA CA3170367A patent/CA3170367A1/en active Pending
- 2021-03-23 JP JP2022553649A patent/JP2023519158A/ja active Pending
- 2021-03-23 US US17/905,601 patent/US20230263778A1/en active Pending
- 2021-03-23 BR BR112022018236A patent/BR112022018236A2/pt unknown
- 2021-03-23 PE PE2022001963A patent/PE20221868A1/es unknown
- 2021-03-23 PH PH1/2022/552324A patent/PH12022552324A1/en unknown
- 2021-03-23 KR KR1020257026443A patent/KR20250126146A/ko active Pending
- 2021-03-23 MX MX2022011370A patent/MX2022011370A/es unknown
- 2021-03-23 CN CN202180021244.6A patent/CN115697328A/zh active Pending
- 2021-03-23 CA CA3280568A patent/CA3280568A1/en active Pending
- 2021-03-23 AU AU2021244718A patent/AU2021244718A1/en active Pending
- 2021-03-23 EP EP25196002.7A patent/EP4628100A3/en active Pending
- 2021-03-23 KR KR1020227035247A patent/KR20220158242A/ko active Pending
- 2021-03-23 CN CN202511049799.8A patent/CN120754260A/zh active Pending
- 2021-03-23 IL IL296152A patent/IL296152A/en unknown
-
2022
- 2022-09-12 MX MX2025008873A patent/MX2025008873A/es unknown
- 2022-09-12 CL CL2022002481A patent/CL2022002481A1/es unknown
- 2022-09-13 DO DO2022000185A patent/DOP2022000185A/es unknown
- 2022-09-30 CO CONC2022/0014073A patent/CO2022014073A2/es unknown
- 2022-09-30 EC ECSENADI202276862A patent/ECSP22076862A/es unknown
- 2022-10-10 ZA ZA2022/11060A patent/ZA202211060B/en unknown
- 2022-10-25 US US18/049,508 patent/US12285413B2/en active Active
-
2025
- 2025-08-01 JP JP2025129731A patent/JP2025166040A/ja active Pending
- 2025-08-15 AU AU2025217394A patent/AU2025217394A1/en active Pending
- 2025-10-06 IL IL323820A patent/IL323820A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519158A5 (https=) | ||
| TWI905508B (zh) | 用於治療病毒感染之方法 | |
| Imran et al. | Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review | |
| US10787502B2 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| JP2022551696A5 (https=) | ||
| CN114340640A (zh) | 用于治疗、改善或预防冠状病毒感染的制造产品和方法 | |
| KR20170031231A (ko) | 파라믹소바이러스의 치료 방법 | |
| TW202241457A (zh) | 用於預防病毒及微生物感染及其等之後遺症之藥物、治療組合、及方法 | |
| AU2004275771A1 (en) | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension | |
| WO2006017505A3 (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases | |
| JP2024546179A5 (https=) | ||
| US20050227949A1 (en) | Compositions and methods for treatment of viral and bacterial infections | |
| AU672022B2 (en) | Antiviral combinations | |
| CN101437525B (zh) | 摩尔比为1:100至1:350的阿洛夫定和齐多夫定的组合 | |
| JP2019515910A5 (https=) | ||
| WO2024129551A1 (en) | Solid dosage form of a small molecule antiviral and uses thereof | |
| TW202606718A (zh) | 用於治療病毒感染之方法 | |
| KR20260043113A (ko) | 소분자 항바이러스제의 고체 투여 형태 및 그의 용도 | |
| HK40091740A (zh) | 用於治疗、改善或预防微生物感染的制造产品和方法 | |
| WO2022049414A1 (es) | Nitazoxanida para su uso en el tratamiento de covid-19 | |
| RU2014116836A (ru) | Амид 1,2,4-триазол-3-илтиогликолевой кислоты, обладающий противовирусной активностью, или его фармацевтически приемлемые соли, фармацевтические композиции и их применение для лечения и профилактики гриппа | |
| Healthcare | New Antimicrobial Agents Approved by the US Food and Drug Administration in 1998 and New Indications for Previously Approved Agents | |
| EP0650362A1 (en) | Antiviral combinations | |
| HK40011695B (en) | Norketotifen for treatment of hypercytokinemia and viral infections | |
| HK40011695A (en) | Norketotifen for treatment of hypercytokinemia and viral infections |